On this page
What each program costs in Delaware
The monthly price is all-in: the drug plus a membership when we have verified one. Compounded drugs are not FDA-approved.
| # | Program | Cheapest product | Plan | All in | Membership fee | Trustpilot | Checked | Seller site |
|---|---|---|---|---|---|---|---|---|
| 1 | Compounded Semaglutide | sale price | $39/mo | not verified | too few reviews | Visit | ||
| 2 | Compounded Semaglutide | 12-month plan, $588 up front | $49/mo | none | 3.9 (11,798 reviews) | Visit | ||
| 3 | Compounded Semaglutide | month to month | $59/mo | none | too few reviews | Visit | ||
| 4 | Compounded Semaglutide | 12-month plan, $828 up front | $69/mo | none | 4.6 (4,268 reviews) | Visit | ||
| 5 | Compounded Semaglutide | medication monthly, membership yearly | $75/mo | $199/yr, included | 4.8 (288 reviews) | Visit | ||
| 6 | Compounded Semaglutide | month to month | $79/mo | none | too few reviews | Visit | ||
| 7 | Compounded Semaglutide | month to month | $99/mo | none | 4.6 (5,235 reviews) | Visit | ||
| 8 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.3 (880 reviews) | Visit | ||
| 9 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.2 (218 reviews) | Visit | ||
| 10 | Compounded Semaglutide | 12-month plan, $1,260 up front | $105/mo | none | too few reviews | Visit | ||
| 11 | Compounded Semaglutide | 12-month plan, $1,698 up front | $141/mo | none | too few reviews | Visit | ||
| 12 | Semaglutide | month to month | $149/mo | none | too few reviews | Visit | ||
| 13 | Compounded Semaglutide | 12-month plan, $1,788 up front | $149/mo | none | 4.2 (777 reviews) | Visit | ||
| 14 | Microdosing Tirzepatide | 12-month plan, $2,028 up front | $169/mo | none | 4.0 (162 reviews) | Visit | ||
| 15 | Compounded Semaglutide | 2-month plan, $350 up front | $175/mo | none | 4.6 (1,084 reviews) | Visit | ||
| 16 | Compounded Oral Semaglutide Capsules | 6-month plan, $1,194 up front | $199/mo | none | too few reviews | Visit | ||
| 17 | Foundayo (brand orforglipron) | medication monthly, membership yearly | $208/mo | $59/mo, billed yearly, included | 4.6 (4,607 reviews) | Visit | ||
| 18 | Sublingual Semaglutide | month to month | $249/mo | none | 4.5 (17,622 reviews) | Visit | ||
| 19 | Compounded Semaglutide | month to month | $299/mo | none | too few reviews | Visit |
Does the State of Delaware Group Health Insurance Plan (non-Medicare) cover GLP-1s for weight loss?
Delaware's state employee prescription plan still covers GLP-1s for weight management such as Wegovy and Zepbound. Since July 1, 2026 non-Medicare members pay a $200 copay per 30-day supply, set by the State Employee Benefits Committee on March 9, 2026.
Delaware Statewide Benefits Office
The Statewide Benefits Office says the Committee voted on March 9, 2026 to raise the weight-management GLP-1 copay to $200 per 30-day supply.
“At the March 9, 2026 State Employee Benefits Committee (SEBC) meeting, the Committee voted to increase the copay to $200 per 30-day supply for GLP-1 medications for weight management, such as Wegovy and Zepbound*, effective July 1, 2026 for non-Medicare prescription plan participants.”
https://dhr.delaware.gov/benefits/cvs/index.shtml · read Oct 29, 2026
Delaware Statewide Benefits Office
The copay applies to every current and future drug in the class.
“The $200 copay will apply to any current and future medications in this drug class.”
https://dhr.delaware.gov/benefits/cvs/index.shtml · read Oct 29, 2026
Does Delaware Medicaid cover GLP-1s for weight loss?
Documents conflict
Delaware Medicaid's documents conflict: the drug list effective October 5, 2026 and an April 2026 form show a route for Wegovy and Zepbound for obesity, while the policy manual revised October 5, 2026 says such drugs are not covered with prior authorization. Read from state documents Nov 6, 2026.
What Delaware Medicaid's documents say about each drug for weight loss. Read Nov 6, 2026. Delaware Department of Health and Social Services, Division of Medicaid and Medical Assistance.
WegovyUnclear
Delaware's documents conflict. The drug list effective October 5, 2026 and the prior authorization form revised April 20, 2026 show a route for obesity with BMI rules. Section 3.5.6.1 of the policy manual, revised October 5, 2026, says these drugs are not covered with prior authorization, while its own revision table says the section was updated to cover them. We do not pick one.
“WEGOVY (semaglutide) pen-injector WEGOVY HD (semaglutide) pen-injector”
Delaware DHSS, Division of Medicaid and Medical Assistance · Effective Oct 5, 2026 · read Nov 6, 2026
“OBESITY TREATMENT AGENTS (Clinical criteria applies to class. All agents require a prior authorization.)”
Delaware DHSS, Division of Medicaid and Medical Assistance · Effective Oct 5, 2026 · read Nov 6, 2026
“Member must have obesity as defined below.”
Delaware DHSS, Division of Medicaid and Medical Assistance · No effective date on the document · read Nov 6, 2026
“Drugs indicated for the treatment of obesity to address weight loss with co-morbid conditions are not covered by DMAP with prior authorization.”
Delaware DHSS, Division of Medicaid and Medical Assistance, Pharmacy Provider Specific Policy Manual · No effective date on the document · read Nov 6, 2026
“Section updated in alignment with the State Plan to cover drugs indicated for the treatment of obesity to address weight loss with co-morbid conditions with prior authorization.”
Delaware DHSS, Division of Medicaid and Medical Assistance, Pharmacy Provider Specific Policy Manual, revision table · Effective Sep 23, 2022 · read Nov 6, 2026
ZepboundUnclear
Delaware's documents conflict. The drug list effective October 5, 2026 and the prior authorization form revised April 20, 2026 show a route for obesity with BMI rules. Section 3.5.6.1 of the policy manual, revised October 5, 2026, says these drugs are not covered with prior authorization, while its own revision table says the section was updated to cover them. We do not pick one.
“ZEPBOUND (tirzepatide) auto-injector ZEPBOUND KWIKPEN (tirzepatide)”
Delaware DHSS, Division of Medicaid and Medical Assistance · Effective Oct 5, 2026 · read Nov 6, 2026
“OBESITY TREATMENT AGENTS (Clinical criteria applies to class. All agents require a prior authorization.)”
Delaware DHSS, Division of Medicaid and Medical Assistance · Effective Oct 5, 2026 · read Nov 6, 2026
“Member must have obesity as defined below.”
Delaware DHSS, Division of Medicaid and Medical Assistance · No effective date on the document · read Nov 6, 2026
“Drugs indicated for the treatment of obesity to address weight loss with co-morbid conditions are not covered by DMAP with prior authorization.”
Delaware DHSS, Division of Medicaid and Medical Assistance, Pharmacy Provider Specific Policy Manual · No effective date on the document · read Nov 6, 2026
“Section updated in alignment with the State Plan to cover drugs indicated for the treatment of obesity to address weight loss with co-morbid conditions with prior authorization.”
Delaware DHSS, Division of Medicaid and Medical Assistance, Pharmacy Provider Specific Policy Manual, revision table · Effective Sep 23, 2022 · read Nov 6, 2026
OzempicNo
Prior authorization under the type 2 diabetes GLP-1 form. Coverage must be for an FDA-approved use, and off-label requests need two peer reviewed articles.
“OZEMPIC injection (semaglutide) TRULICITY (dulaglutide)”
Delaware DHSS, Division of Medicaid and Medical Assistance · Effective Oct 5, 2026 · read Nov 6, 2026
“A glucagon-like peptide-1 (GLP-1) agonist indicated for type 2 diabetes mellitus (T2DM) will be approved if the following criteria are met”
Delaware DHSS, Division of Medicaid and Medical Assistance · No effective date on the document · read Nov 6, 2026
“All other indications will be considered experimental and may not be covered.”
Delaware DHSS, Division of Medicaid and Medical Assistance · No effective date on the document · read Nov 6, 2026
MounjaroNo
Prior authorization under the type 2 diabetes GLP-1 form. Coverage must be for an FDA-approved use, and off-label requests need two peer reviewed articles.
“MOUNJARO (tirzepatide) OZEMPIC injection (semaglutide)”
Delaware DHSS, Division of Medicaid and Medical Assistance · Effective Oct 5, 2026 · read Nov 6, 2026
“A glucagon-like peptide-1 (GLP-1) agonist indicated for type 2 diabetes mellitus (T2DM) will be approved if the following criteria are met”
Delaware DHSS, Division of Medicaid and Medical Assistance · No effective date on the document · read Nov 6, 2026
“All other indications will be considered experimental and may not be covered.”
Delaware DHSS, Division of Medicaid and Medical Assistance · No effective date on the document · read Nov 6, 2026
This reports what the documents say. It is not medical or legal advice: your plan and your prescriber decide.
What changed, and when
- Nov 6, 2026 · This pageFirst read from state documents. KFF's January 2026 map listed this program as covered; the state's documents conflict with each other.
Weight loss
Documents conflict, read Nov 2026
Type 2 diabetes
Required in every state
Heart risk, sleep apnea
Required (Wegovy, Zepbound)
Prior authorization
Typical when covered
Wegovy, Zepbound, Saxenda, 2025
31,647 prescriptions
Ozempic and Mounjaro, 2025
20,121 prescriptions
Neighbours covering weight loss
0 of 3
Federal law lets each state decide whether Medicaid pays for drugs used for weight loss, while drugs approved for diabetes must be covered. A state document may not settle every plan; if your Delaware Medicaid coverage comes through a managed care plan, its formulary can differ, so ask the plan before you fill.
For comparison, a dated secondary source: KFF's January 2026 map listed Delaware Medicaid as "covered" for GLP-1s for obesity under fee-for-service.
The BALANCE model
CMS’s BALANCE model lets state Medicaid programs add GLP-1s for weight management at a negotiated price. States could join on a rolling basis from May 1, 2026 through January 1, 2027, and the state application deadline was July 31, 2026. We could not find a published list of the states that joined, so this page does not say whether Delaware Medicaid did. Ask your plan. Either way your cost stays at Medicaid’s nominal copay, which BALANCE does not change.
The national picture, coupons and patient assistance: does Medicaid cover GLP-1s.
How many GLP-1s does Delaware Medicaid pay for?
55,674 GLP-1 prescriptions in 2025, 35th of the 50 states and DC, with $20.1 million reimbursed before rebates. Counting the share other payers covered, $21.4 million.
Prescriptions, 2025
55,674
35th of 51
Medicaid paid
$20.1M
46th of 51, before rebates
Per prescription
$362
$1,051 nationally
Weight-loss brands
57%
4th highest share of 51
CMS State Drug Utilization Data 2025, updated Jul 13, 2026, fee-for-service and managed care, before rebates. Delaware is highlighted. CMS publishes this comparison as one year, not a trend.
Wegovy, Zepbound and Saxenda, the brands approved for weight management, were 57% of Delaware Medicaid's GLP-1 prescriptions in 2025 (31,647). Across the 13 states KFF lists as covering GLP-1s for obesity, the median share was 52%; across the other 38, 2.3%. Where weight loss is not covered, those brands are mostly filled for the uses Medicaid must cover, such as heart risk and sleep apnea. Wegovy was Delaware Medicaid's most filled GLP-1.
| Brand | Prescriptions | Share | Medicaid paid | Per Rx |
|---|---|---|---|---|
| Wegovyapproved for weight management | 18,765 | 34% | $996 | $0 |
| Ozempic | 17,134 | 31% | $16.4 million | $960 |
| Zepboundapproved for weight management | 12,784 | 23% | $2,886 | $0 |
| Trulicity | 3,481 | 6.3% | $3.3 million | $940 |
| Mounjaro | 2,987 | 5.4% | $1,319 | $0 |
| Rybelsus | 414 | 0.7% | $397,959 | $961 |
| Saxendaapproved for weight management | 98 | 0.2% | $2,091 | $21 |
| Bydureon | 11 | 0.0% | $7,391 | $672 |
Source: CMS State Drug Utilization Data 2025, updated Jul 13, 2026, all four quarters, fee-for-service and managed care. Before rebates. CMS suppresses rows under 11 prescriptions, so small brands are undercounted slightly. Every state ranked: prescriptions and spending.
On Medicare in Delaware?
Medicare’s temporary GLP-1 Bridge works the same in every state: a $50 copay for a one-month supply of Wegovy, Foundayo or the Zepbound KwikPen, for people with Part D who meet its weight and health rules.
medicare.gov
“You’ll pay a $50 copayment to the pharmacy for a one-month supply (either 28 or 30 days, depending on drug).”
https://www.medicare.gov/coverage/weight-loss-drugs · read Nov 14, 2026
Delaware and the states around it
Medicaid’s weight-loss answer (the state’s own documents where we have read them, otherwise KFF, January 2026) and the partner programs that ship there, priced the same way as above.
None of the 3 states next to Delaware covers GLP-1s for weight loss through Medicaid. None has a lower cash floor than Delaware's $39.
| State | Medicaid, weight loss | Ship there | Cheapest that ships there |
|---|---|---|---|
| Delaware | Documents conflict | 19 | $39/mo |
| Maryland | Not covered | 19 | $39/moWellmedr |
| New Jersey | Not covered | 19 | $39/moWellmedr |
| Pennsylvania | Not covered | 19 | $39/moWellmedr |






















